The information in this section is intended for visitors outside the United States.
Over the past decade, international efforts have greatly increased the number of people in developing countries receiving antiretroviral therapy to treat HIV/AIDS. Today, 11.7 million people in the developing world are receiving therapy, although more than 35 million people worldwide are living with HIV.
Viread® (tenofovir disoproxil fumarate) and Truvada® (emtricitabine/tenofovir disoproxil fumarate) are recommended by the World Health Organization as components of antiretroviral therapy. We make these medicines available in low- and middle-income countries through two means:
Our single tablet regimens Atripla® (efavirenz/emtricitabine/tenofovir disoproxil fumarate) and Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) were developed and are distributed through joint ventures with Merck and Janssen Therapeutics, respectively. We work with these companies to manage access for developing countries.
Also, as new HIV medicines advance through the research and development pipeline, we take steps to introduce them through access programs. For example, in July 2014, Gilead expanded its MPP licensing agreements by granting generic manufacturers in India and China future rights to develop its investigational drug, tenofovir alafenamide (TAF), for the treatment of HIV and hepatitis B in 112 resource-limited countries, contingent on the medicine’s U.S. regulatory approval.